Mizuho upgraded Amylyx (AMLX) to Outperform from Neutral with a price target of $7, up from $3, after introducing first-time projections for avexitide in post-bariatric hypoglycemia as well as adding back model contributions from AMX0035 in progressive supranuclear palsy and Wolfram Syndrome.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
- Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market
- Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation
- Amylyx Pharmaceuticals Reports 2024 Financial Results
- Amylyx Pharmaceuticals’ Earnings Call Highlights Clinical Progress